Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

28.00 -12.61 (-31.05%)
Streaming Delayed Price Updated: 3:56 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MiNK Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Which stocks are moving on Tuesday?
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
A Look at MiNK Therapeutics's Upcoming Earnings Report
Via Benzinga
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy 
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
These stocks are moving in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Unusual volume stocks in Monday's session
Unusual volume stocks in Monday's session 
Via Chartmill
Which stocks are moving on Monday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Monday's pre-market session: top gainers and losers
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Datavault AI Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Topics Artificial Intelligence
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
What's going on in today's after hours session
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?
MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with... 
Via Benzinga
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings
Via Benzinga
Topics Stocks
MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy
“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company said. 
Via Stocktwits
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors 
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settings 
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
From MiNK Therapeutics
Via GlobeNewswire
Earnings Scheduled For May 15, 2025
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.